Royalty Pharma plc - RPRX STOCK NEWS

Royalty Pharma (RPRX) reported strong financial results for 2021, with net cash from operations of $490 million. Adjusted Cash Receipts reached $2,129 million, a notable 18% increase year-over-year. The company announced $3 billion in transactions, including $2.3 billion in upfront payments, enhancing its diverse portfolio. 2022 guidance forecasts Adjusted Cash Receipts between $2,225 million and $2,300 million. Despite a 13% decline in Q4 operating cash flow, the firm remains confident in its growth trajectory, supported by multiple positive clinical updates and expanding royalty interests.

Royalty Pharma (RPRX) will report its fourth-quarter and full-year 2021 financial results on February 15, 2022, before market opening. The company will host a conference call at 8:00 a.m. ET, accessible via phone and webcast. Royalty Pharma, founded in 1996, is a major player in biopharmaceutical royalties, partnering with various organizations to fund innovation. Its portfolio includes royalties on over 40 commercial products from leading pharmaceutical companies, showcasing its extensive involvement in the sector.

ProKidney, a clinical-stage cellular therapeutics company, has initiated a business combination with Social Capital Suvretta Holdings Corp. III (DNAC). This partnership aims to accelerate the development of REACT®, a first-of-its-kind autologous cell therapy targeting chronic kidney disease (CKD), which has received RMAT designation. The deal values the combined entity at $2.64 billion and is projected to provide $825 million in gross cash proceeds to support REACT®'s Phase 3 clinical trials and manufacturing efforts. The patient population for REACT® exceeds 75 million across the U.S. and the EU.

Royalty Pharma (RPRX) provides a business performance update, projecting 2021 Net cash from operating activities between $2,010 and $2,030 million and Adjusted Cash Receipts at $2,110 to $2,130 million, an 18% increase year-over-year. The company added 20 therapies to its portfolio, with 9 expected to be blockbusters. Recent transactions valued at $5.5 billion aim to boost Adjusted Cash Receipts by over $750 million in 2025. The CEO highlights strong capital deployment and innovation funding as key growth drivers.

Royalty Pharma has announced its investment in Cytokinetics, providing up to $300 million for the commercialization of omecamtiv mecarbil and development of aficamten. The funds will be distributed in five tranches, with an initial $50 million upon closing. Additionally, Royalty Pharma has acquired a 4.5% royalty on aficamten sales up to $1 billion. Cytokinetics aims to utilize this funding to secure a cash runway for at least two years, enhancing its position in the cardiovascular market.

Royalty Pharma plc (Nasdaq: RPRX) announced a 12% increase in its quarterly dividend, now set at $0.19 per Class A share for Q1 2022. The dividend will be paid on March 15, 2022, to shareholders of record as of February 18, 2022. This reflects Royalty Pharma's ongoing commitment to returning value to its shareholders while leveraging its extensive portfolio of biopharmaceutical royalties.

Royalty Pharma (Nasdaq: RPRX) will present at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 8:15 a.m. ET. The conference offers a platform for the company to showcase its position as the largest buyer of biopharmaceutical royalties.

The webcast will be available on Royalty Pharma's Events page and archived for at least thirty days. Established in 1996, the company collaborates to fund innovation and holds royalties on over 40 leading therapies.

Royalty Pharma plc (Nasdaq: RPRX) will participate in the Evercore ISI 4th Annual HealthCONx Virtual Conference on December 2, 2021, at 9:40 a.m. ET. The event will include a fireside chat accessible via the company’s Events page, with the webcast archived for at least thirty days. Founded in 1996, Royalty Pharma is a leader in funding biopharmaceutical innovation, holding royalties on approximately 40 commercial products from major pharmaceutical companies, facilitating advancements in healthcare.

On November 22, 2021, Royalty Pharma (RPRX) and OMERS Capital Markets announced $350 million funding for BioCryst Pharmaceuticals (BCRX). This capital will support the advancement of BCX9930, an oral Factor D inhibitor, and further investment in the global launch of ORLADEYO^® (berotralstat), which targets hereditary angioedema (HAE). Royalty Pharma's agreement includes royalties on sales and a $50 million equity investment in BioCryst at $13.00 per share. The funds will accelerate pivotal trials and regulatory filings for BCX9930, reinforcing BioCryst's growth strategy.